$IVVD News

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

Invivyd’s Covid-directed mAb hits Phase III safety goals

Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow

Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine

BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target

Invivyd to Participate in Upcoming September Investor Conferences

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026

Invivyd Appoints Marc Elia As CEO

Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Target